Ivermectin (Pharma Grade)

Product Overview

Ivermectin is a macrocyclic lactone antiparasitic agent discovered by Satoshi Omura and William C. Campbell, recognized with the 2015 Nobel Prize in Physiology or Medicine. It is listed on the WHO Model List of Essential Medicines and has revolutionized the treatment of neglected tropical diseases worldwide. Its mechanism involves potent and selective binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells.

This pharmaceutical-grade Ivermectin has been instrumental in global mass drug administration programs targeting onchocerciasis (river blindness) and lymphatic filariasis. Beyond its antiparasitic indications, this API also supports topical dermatological formulations for conditions such as rosacea, demonstrating remarkable versatility in human medicine.

Quality Specifications

Purity	As per EP/USP/IN HOUSE monograph
Residual Solvents	Compliant with ICH Q3C
Heavy Metals	Compliant with pharmacopoeia limits
GMP Status	Manufactured under GMP conditions

Pharmaceutical Applications

Therapeutic Indications

• Onchocerciasis (River Blindness): Mass drug administration to control Onchocerca volvulus transmission
• Lymphatic Filariasis: In combination with albendazole for elimination programs
• Strongyloidiasis: Treatment of chronic Strongyloides stercoralis infection
• Scabies: Oral treatment for crusted and ordinary scabies
• Head Lice: Topical lotion for pediculosis capitis
• Rosacea: Topical 1% cream for inflammatory lesions of papulopustular rosacea